Table 2.
Participant Characteristics by Tertiles of Baseline Serum 1,25(OH)2D (n = 273)
| White participants | Black participants | |||||||
|---|---|---|---|---|---|---|---|---|
| Range (pg/ml) | Tertile 1 5.9–40.2 | Tertile 2 40.3–51.3 | Tertile 3 51.4–96.9 | p | Tertile 1 5.9–40.2 | Tertile 2 40.3–51.3 | Tertile 3 51.4–96.9 | p |
| N | 66 | 61 | 60 | 24 | 32 | 30 | ||
| Age, mean (SD) | 46.9 (8.6) | 49.1 (8.47) | 48.1 (8.19) | .39 | 41.5 (8.41) | 43.59 (8.66) | 43.57 (8.51) | .40 |
| No college education, % (n) | 15.2 (10) | 13.1 (8) | 6.7 (4) | .31 | 29.2 (7) | 50 (16) | 50 (15) | .22 |
| Annual income <$20,000, % (n) | 30.3 (20) | 31.1 (19) | 18.3 (11) | .20 | 58.3 (14) | 65.6 (21) | 76.7 (23) | .35 |
| BMI, mean (SD)a | 25.1 (4.31) | 25.0 (3.3) | 26.2 (4.02) | .15 | 26.17 (5.07) | 25.36 (3.66) | 28.16 (8.2) | .22 |
| Prevalent diabetes, % (n)a | 5.9 (2) | 8.1 (3) | 4.5 (2) | .80 | 22.2 (4) | 4 (1) | 4.3 (1) | .08 |
| Prevalent hypertension, % (n)a | 29.5 (18) | 27.6 (16) | 39.7 (23) | .33 | 16.7 (4) | 36.7 (11) | 37.9 (11) | .18 |
| eGFR, mean (SD) | 92.2 (14.5) | 92.7 (14.2) | 90.7 (15.6) | .58 | 106.57 (20.99) | 107.74 (19.49) | 102.53 (21.68) | .45 |
| CD4+ lymphocyte count/ml median (1st, 3rd quartile) | 537 (344, 651) | 513 (373, 787) | 569 (428, 707) | .58 | 393 (241, 556) | 415 (334, 647) | 511 (363, 757) | .26 |
| Viral load >50 copies/ml, % (n) | 24.6 (16) | 18.3 (11) | 20 (12) | .67 | 43.5 (10) | 37.5 (12) | 41.4 (12) | .90 |
| Tenofovir use, % (n) | 4.5 (3) | 6.6 (4) | 13.3 (8) | .19 | 12.5 (3) | 18.8 (6) | 10 (3) | .63 |
| Atazanavir use, % (n) | 3 (2) | 9.8 (6) | 16.7 (10) | .03 | 12.5 (3) | 15.6 (5) | 10.3 (3) | .92 |
| Efavirenz use, % (n) | 19.7 (13) | 21.7 (13) | 16.9 (10) | .81 | 29.2 (7) | 28.1 (9) | 16.7 (5) | .47 |
| Enrolled during the Third Enrollment (2001–2003) | 31.8 (21) | 26.2 (16) | 36.7 (22) | .47 | 75 (18) | 71.9 (23) | 86.7 (26) | .34 |
| Center, % (n) | .67 | .19 | ||||||
| Baltimore | 27.3 (18) | 29.5 (18) | 35 (21) | 37.5 (9) | 15.6 (5) | 36.7 (11) | ||
| Chicago | 18.2 (12) | 14.8 (9) | 16.7 (10) | 41.7 (10) | 43.8 (14) | 26.7 (8) | ||
| Pittsburgh | 48.5 (32) | 44.3 (27) | 35 (21) | 12.5 (3) | 15.6 (5) | 6.7 (2) | ||
| Los Angeles | 6.1 (4) | 11.5 (7) | 13.3 (8) | 8.3 (2) | 25 (8) | 30 (9) | ||
| Number of eGFR measures, median (1st, 3rd quartile) | 12.5 (7, 20) | 15 (9, 20) | 12 (8.5, 19) | .80 | 11.5 (6, 16.5) | 13 (9, 18) | 13.5 (7, 19) | .44 |
a
Sample sizes for BMI were 173 in white participants and 80 in black participants, prevalent diabetes 115 in white participants and 66 in black participants, prevalent hypertension 177 in white participants and 83 in black participants, CD4+ cell count 184 in white participants and 85 in black participants, and viral load 185 in white participants and 84 in black participants.